GmmaTech

Interpace Diagnostics Group stock (IDXG) is down: expect recover

NASDAQ:IDXG   None
There are some positive commercial developments for the company. The mega-insurer Cigna stated it will cover ThyraMIR, a microRNA gene expression classifier for thyroid nodules, that Interpace Diagnostics developed.

The health insurer has covered another IDXG's drug ThyGenX since 2017. 80% of ThyGenX orders are coupled with an order for ThyraMIR, and the two tests are billed independently.

www.finstead.com/bit...diction-july-25-2018


면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.